1. You Are At:
  2. English News
  3. Business
  4. India's second coronavirus vaccine by Zydus Cadila gets DCGI nod for human clinical trials

India's second coronavirus vaccine by Zydus Cadila gets DCGI nod for human clinical trials

The approval process was fast-tracked following a recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic.

India TV Business Desk India TV Business Desk
New Delhi Updated on: July 03, 2020 11:25 IST
A couple of days earlier, the country's 'first' indigenous COVID-19 vaccine candidate Covaxin, devel
Image Source : FILE

A couple of days earlier, the country's 'first' indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech.

After Bharat Biotech's Covaxin, another potential COVID-19 vaccine indigenously developed by Ahmedabad-based Zydus Cadila Healthcare Ltd got nod from the Drugs Controller General of India (DCGI) on Thursday for human clinical trials.

Permission for Phase I/II clinical trial for COVID-19 vaccine of Zydus Cadila granted today as a rapid response after recommendation by Subject Expert Committee said a Health Ministry official.

The approval process was fast-tracked following a recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic.

"DCGI Dr V G Somani has given approval for the phase I and II clinical trials (on humans) of the potential novel coronavirus vaccine developed by Zydus Cadila Healthcare Ltd on Thursday after its animal studies was found to be successful," an official source in the know of the developments told PTI.

The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity, sources said.

The company is likely to start enrolment of subjects soon.

"The phase I and II trials will take around three months to be completed," the source said.

A couple of days earlier, the country's 'first' indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indican Council of Medical Research and National Institute of Virology (NIV), had got the nod for human clinical trials from the DCGI.

The union health ministry, meanwhile, has revised the home isolation guidelines to include asymptomatic positive patients in the list of mild or pre-symptomatic coronavirus infection cases.

India's COVID-19 tally rose to 6,04,641 on Thursday with a single-day increase of 19,148 cases, just five days after it crossed the five-lakh mark, while the death toll rose to 17,834 with 434 new fatalities, according to the Union Health Ministry.

(With PTI inputs)

Latest News on Coronavirus

Latest Business News

Fight against Coronavirus: Full coverage

Write a comment

X